Literature DB >> 16563819

Cross-sectional evaluation of patient functioning and health-related quality of life in patients with neuropathic pain under standard care conditions.

Rafael Gálvez1, Carlos Marsal, Javier Vidal, Manuel Ruiz, Javier Rejas.   

Abstract

AIM: The purpose of this cross-sectional evaluation was to determine the impact of neuropathic pain (NeP) on patient functioning and Health-Related Quality of Life (HRQoL) under standard care conditions.
METHODS: Patients with NeP or neuropathic and nociceptive pain [Mixed Pain (MP)] enrolled in the DONEGA study, a naturalistic, prospective and multi-centre study of the effectiveness of gabapentin under usual care conditions, were included in this cross-sectional evaluation before starting study treatments. Participants completed the Short Form-McGill Pain Questionnaire, MOS Short Form-12 (SF-12), and Sheehan Disability Scale (ShDS). Multivariate analysis and regression models were used to analyze patient data.
RESULTS: A total of 1519 patients [mean+/-SD; 56.0+/-13.7 yrs old (58.8% female)] with NeP or MP were enrolled in the study. The mean pain history was 1.1+/-2.8 yrs, current pain intensity on a 5-point visual analogue scale was 2.8+/-1.0 and mean pain in previous week was 71.3+/-19.0mm. Pain substantially interfered (i.e., score > or = 5 on 0-10 scale) with normal work (5.9+/-3.0), social life (5.7+/-3.0), and family life (5.3+/-3.0), producing substantial disability (total ShDS score of 16.9+/-8.3 pts). Country-standardised physical (PCS) and mental health (MCS) component summary scores of SF-12 indicated significant impairment in both domains compared with the general Spanish population: PCS; -1.13+/-1.0 SDS (standard deviation score), and MCS; -1.21+/-0.7 SDS, equivalent to the 15th and 25th percentiles of normative populations, respectively.
CONCLUSIONS: Under standard care conditions, neuropathic and mixed pain are associated with impaired physical and mental QoL, producing a substantial level of disability in these patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16563819     DOI: 10.1016/j.ejpain.2006.02.002

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  22 in total

1.  Chronic neuropathic pain negatively associated with employment retention of cancer survivors: evidence from a national French survey.

Authors:  Caroline Alleaume; Marc-Karim Bendiane; Anne-Déborah Bouhnik; Dominique Rey; Sébastien Cortaredona; Valérie Seror; Patrick Peretti-Watel
Journal:  J Cancer Surviv       Date:  2017-10-04       Impact factor: 4.442

2.  Reversal of peripheral nerve injury-induced neuropathic pain and cognitive dysfunction via genetic and tomivosertib targeting of MNK.

Authors:  Stephanie Shiers; Juliet Mwirigi; Grishma Pradhan; Moeno Kume; Bryan Black; Paulino Barragan-Iglesias; Jamie K Moy; Gregory Dussor; Joseph J Pancrazio; Sven Kroener; Theodore J Price
Journal:  Neuropsychopharmacology       Date:  2019-10-07       Impact factor: 7.853

3.  Mediators and moderators of change in mindfulness-based stress reduction for painful diabetic peripheral neuropathy.

Authors:  Karolina A Rozworska; Patricia A Poulin; Amanda Carson; Giorgio A Tasca; Howard J Nathan
Journal:  J Behav Med       Date:  2019-07-15

4.  Pain alleviation and patient-reported health outcomes following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain in routine medical practice.

Authors:  María T Saldaña; Concepción Pérez; Ana Navarro; Xavier Masramón; Javier Rejas
Journal:  Clin Drug Investig       Date:  2012-06-01       Impact factor: 2.859

5.  Pain, neuropathic symptoms, and physical and mental well-being in persons with cancer.

Authors:  Cindy S Tofthagen; Susan C McMillan
Journal:  Cancer Nurs       Date:  2010 Nov-Dec       Impact factor: 2.592

6.  Neuropathic Pain Creates an Enduring Prefrontal Cortex Dysfunction Corrected by the Type II Diabetic Drug Metformin But Not by Gabapentin.

Authors:  Stephanie Shiers; Grishma Pradhan; Juliet Mwirigi; Galo Mejia; Ayesha Ahmad; Sven Kroener; Theodore Price
Journal:  J Neurosci       Date:  2018-07-20       Impact factor: 6.167

7.  The relationship between mindfulness, pain intensity, pain catastrophizing, depression, and quality of life among cancer survivors living with chronic neuropathic pain.

Authors:  Patricia A Poulin; Heather C Romanow; Noriyeh Rahbari; Rebecca Small; Catherine E Smyth; Taylor Hatchard; Brahm K Solomon; Xinni Song; Cheryl A Harris; John Kowal; Howard J Nathan; Keith G Wilson
Journal:  Support Care Cancer       Date:  2016-05-18       Impact factor: 3.603

8.  Prevalence and characterization of neuropathic pain in a primary-care setting in Spain: a cross-sectional, multicentre, observational study.

Authors:  Concepción Pérez; María Teresa Saldaña; Ana Navarro; Inma Vilardaga; Javier Rejas
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

9.  Adding pregabalin or gabapentin for the management of community-treated patients with painful diabetic peripheral neuropathy: a comparative cost analysis.

Authors:  Antoni Sicras; Javier Rejas; Ruth Navarro; Albert Planas
Journal:  Clin Drug Investig       Date:  2013-11       Impact factor: 2.859

Review 10.  Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy.

Authors:  Alec B O'Connor
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.